Physician profile
Joseph Jose
NPI 1134326150
$3,044.07
in general payments reported to CMS, 2019-2025
20 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $201 · 2021: $301 · 2022: $390 · 2023: $632 · 2024: $557 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $599.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $338.79 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $321.45 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $305.22 | 2019-2025 | |
| Exact Sciences Corporation | $266.70 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $252.63 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.54 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $161.09 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $160.49 | 2023-2025 | |
| Phadia US INC. | $94.93 | 2022-2023 | Immunocap |
| Janssen Pharmaceuticals, INC | $61.00 | 2019-2024 | Xarelto |
| Abbvie INC. | $59.85 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $53.77 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.34 | 2022 | |
| Intra-Sana Laboratories | $19.17 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.66 | 2019 | |
| Almatica Pharma LLC | $16.65 | 2022 | |
| Amarin Pharma, INC. | $16.20 | 2020 | |
| Astellas Pharma US INC | $15.42 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.